Clinical Trial

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-21; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2026-02-06
Trial Details
NCT Number NCT07357519
Lead Sponsor Lantheus Medical Imaging
Conditions Relapsed / Refractory Osteosarcoma
Enrollment 55 participants
Start Date 2026-02-03
Primary Completion 2027-08 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-01